-
Rodman & Renshaw Reiterates Idera Pharmaceuticals Market Outperform, Lowers PT
Thursday, July 14, 2011 - 4:57pm | 97Rodman & Renshaw reiterated its Idera Pharmaceuticals (IDRA) Market Outperform rating and lowered its Idera Pharmaceuticals price target from $6 to $4 in a research report published today. In the report, Rodman & Renshaw states, "Despite setbacks, Idera has multiple products in the...
-
Cubist Pharmaceuticals Bid Higher on Earnings Results
Thursday, July 14, 2011 - 4:49pm | 202Shares of Cubist Pharmaceuticals (NASDAQ: CBST) are bid higher in the after-hours following the release of the company's Q2 earnings results. Currently, shares are bid $36.02, at $37.49; they ended the regular session lower by 1.13%, at $35.93. Cubist Pharmaceuticals reported Q2 non-GAAP diluted...
-
BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
Thursday, July 14, 2011 - 4:42pm | 139BioMarin Pharmaceutical (Nasdaq: BMRN) today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase inhibitor, for the treatment of patients with advanced hematological malignancies. A Phase 1/2 trial for BMN 673 for the treatment of patients with solid tumors was...
-
Seattle Genetics Announces Unanimous Recommendations from FDA Advisory Committee
Thursday, July 14, 2011 - 4:34pm | 124Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the Oncologic Drugs Advisory Committee to the U.S. Food and Drug Administration voted 10-0 to recommend that the FDA grant accelerated approval of ADCETRIS for the treatment of patients with Hodgkin lymphoma who relapse after autologous...
-
Vical and Astellas Announce Worldwide License Agreements for TransVax(TM) Cytomegalovirus Vaccine
Thursday, July 14, 2011 - 4:02pm | 313Vical Incorporated (Nasdaq: VICL) and Astellas Pharma Inc. today announced that they have signed exclusive license agreements for the United States and for all territories in the rest of world outside the United States to develop and commercialize TransVax™, Vical's therapeutic vaccine designed to...
-
Update On Seattle Genetics FDA Meeting
Thursday, July 14, 2011 - 3:01pm | 66TheStreet.com's Adam Feuerstein is tweeting about the Seattle Genetics (NASDAQ: SGEN) FDA meeting. Feuerstein just tweeted that the FDA panel is moving to questions and voting on Adcetris in ALCL. The FDA voted 10-0 to recommend accelerated approval of Seattle Genetics' Adcetris. Shares have...
-
Wedbush Reiterates Outperform On Cubist Pharmaceuticals
Thursday, July 14, 2011 - 1:54pm | 119Wedbush Securities is reiterating its Outperform rating and $40 price target on shares of Cubist Pharmaceuticals (NASDAQ: CBST). In a note to clients, Wedbush Securities writes, "Our Q2:11 CUBICIN sales estimate is $166.0 million (versus consensus of $165.5 million), our top-line estimate is $174....
-
FDA Advisory Panel Votes 10-0 for Fast Approval of Seattle Genetics Hodgkin Drug
Thursday, July 14, 2011 - 11:36am | 21Panel says Seattle Genetics (NASDAQ: SGEN) should do follow-up trial for regular approval.
-
Cephalon Shareholders Approve Acquisition by Teva
Thursday, July 14, 2011 - 11:06am | 81Cephalon, Inc. (Nasdaq: CEPH) today announced that its stockholders voted to approve the Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) proposal to acquire Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. The transaction remains under review by...
-
NASDAQ Stocks Hitting 52-Week Highs
Thursday, July 14, 2011 - 10:18am | 132Shire plc (NASDAQ: SHPGY) shares rose 1.41% to create a new 52-week high of $100.52. SHPGY's trailing-twelve-month ROE is 26.25%. Infinity Pharmaceuticals Inc (NASDAQ: INFI) shares gained 0.56% to create a new 52-week high of $9.05. INFI had $90.52 million in total cash and no debt for the latest...
-
Biggest Gainers Pre-Market Going Into the Opening Bell
Thursday, July 14, 2011 - 9:20am | 120Cypress Semiconductor (NASDAQ: CY) is trading up over 14% after Collins Stewart reiterated its Buy rating on the company. Seattle Genetics (NASDAQ: SGEN) is trading up over 13% before the stock was halted. ConocoPhillips (NYSE: COP) is trading up over 8% after announcing plans to split into two...
-
Last Nights Noteables July 14th
Thursday, July 14, 2011 - 8:44am | 312Today: (SGEN) Trading of Seattle Genetics Common Stock Halted Jul 14 at 07:08 Profile hits: QU1 JPMorgan Chase & Co. (JPM) Tops Q2 Estimates - Seeing Upside Pre-Bell Range of 40 to 40.44 4:10p (T3) Tim_K: YUM beats and boost 4:10p (T3) Tim_K: threw the daily highs 4:11p michael: B some DRI...
-
Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
Thursday, July 14, 2011 - 8:06am | 192Neuralstem, Inc. (NYSE: CUR) announced that it has received notice of allowance for U.S. Patent Applications 12/939,897 and 12/939,914 entitled: "Compositions to Effect Neuronal Growth." The patents cover three new compounds and include both structure and method claims for inducing neurogenesis...
-
A Peek Into The Market Before The Trading Starts
Thursday, July 14, 2011 - 7:33am | 408Pre-open movers US stock futures are mixed this morning. Futures on the Dow Jones Industrial Average dropped 13 points to 12,412.00 and futures on the S&P 500 stock index fell 0.40 points to 1,311.80. Nasdaq 100 futures climbed 5.50 points to 2,350.00. A Peek Into Global Markets Asian...
-
UPDATE: Seattle Genetics Common Stock Halted; FDA to Discuss Company's Application for ADCETRIS
Thursday, July 14, 2011 - 7:10am | 102Seattle Genetics, Inc. (Nasdaq: SGEN) announced that NASDAQ has halted trading of the company's common stock. The U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee is meeting today to discuss the company's Biologics License Applications for ADCETRIS™ (brentuximab vedotin)....